MolNFT v1 · #85726 · protein + RNA
Crystal structure of the CSY4-minimal crrna complex
4AL7 · CSY4 endoribonuclease: “Crystal structure of the CSY4-minimal crrna complex”. X-ray diffraction, 1 pocket (best druggability 0.31). MolNFT v1 #85726 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 4AL7
- Type
- protein + RNA
- Length
- 170 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- CSY4 endoribonuclease; 5'-R(*CP*UP*GP*CP*CP*GP*UP*AP*UP*AP*GP*GP*CP*AP*G)-3'
- UniProt
- Q02MM2
- Pockets
- 1 · best druggability 0.31
Structure
x-ray diffraction · 2 distinct chains · 19% helix, 30% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | CSY4 endoribonuclease | protein | 155 | 19% helix, 30% strand | Q02MM2 |
| B | 5'-R(*CP*UP*GP*CP*CP*GP*UP*AP*UP*AP*GP*GP*CP*AP*G)-3' | rna | 15 | — | — |
Pockets
1 pocket found on a 1 Å grid, 0 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 50 | 0.31 | 0.77 | 13 | empty |
Interfaces
1 interface between chains.
- A–B · 425 Ų buried · 6 hydrogen bonds · protein-nucleic
Compared structures
- 4AL7 · Crystal structure of the Csy4-minimal crRNA complex · the same entry in another collection · chain A against A, TM-score 1.00
- Q02MM2 · AlphaFold monomer V2.0 prediction for CRISPR-associated endonuclease CAS6/CSY4 (Q02MM2) · a predicted model of the same protein · chain A against A, TM-score 0.97
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q02MM2
- Elsewhere: RCSB PDB 4AL7 · PDBe 4AL7 · UniProt Q02MM2
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.